SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced the pricing of its initial public offering of 18,425,000 American depositary shares (ADSs), each representing two ordinary shares, at a public offering price of $23.00 per ADS, for total gross proceeds of approximately $423.8 million. In addition, Legend Biotech has granted the underwriters a 30-day option to purchase up to an additional 2,763,750 ADSs at the public offering price, less underwriting discounts and commissions. All of the ADSs are being offered by Legend Biotech.

The shares are scheduled to begin trading on the Nasdaq Global Select Market on June 5, 2020 under the ticker symbol “LEGN.” The offering is expected to close on June 9, 2020, subject to customary closing conditions.

Morgan Stanley, J.P. Morgan and Jefferies are serving as joint book-running managers for the offering.

About Legend Biotech

Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our team of over 650 employees across the United States, China and Europe, along with our differentiated technology, global development, and manufacturing strategies and expertise, provide us with the strong potential to discover, develop, and manufacture best-in-class cell therapies for patients in need.